In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Opexa Pharmaceuticals Inc.

This article was originally published in Start Up

Executive Summary

Opexa Pharmaceuticals was founded in February 2001 to develop therapeutic vaccines for autoimmune diseases. Based on techniques designed by co-founder Jingwu Zhang of Baylor College of Medicine, its first product is a vaccine comprised of autologous myelin-reactive T-cells that stimulate the immune response of patients with multiple sclerosis. The selectivity of the process enables greater efficacy with fewer side effects than existing therapies for MS.

You may also be interested in...



New Approaches to Treating Autoimmune Diseases

In the past few years, new classes of biologics have revolutionized treatment of autoimmune diseases, especially multiple sclerosis, rheumatoid arthritis, psoriasis, and asthma. Biologics tend to be most effective because they work on specific targets and impact the underlying causes of disease. In addition to new biologics, a number of companies and academic researchers are looking at expanding applications for certain cancer drugs to autoimmune diseases. The rationale behind this is straightforward: both diseases have inflammatory effects and require cytotoxic approaches. However, for all the difficulties scientists have had in understanding cancer, they've had even more in trying to figure out autoimmune diseases. Autoimmune diseases tend to have systemic effects and thus it's hard to pinpoint a single site of disease.

Can-Fite BioPharma Ltd.

Israeli start-up Can-Fite is developing small-molecule agonists of the adenosine A3 receptor, having come to its lead compound (in-licensed from the NIH) in the course of investigating why cancer never metastasizes to muscle tissue. The firm says mechanistic studies indicate that its lead compound could also treat inflammatory conditions like rheumatoid arthritis.

Making The Most Of ACOs: How Biopharma Is Adapting To New Customer Segment

ACOs have been one of the most hyped innovations in the US health care sector this decade. The buzz may be overdone, but ACOs are now established as a different—and confusing—new customer segment for pharma. How is industry adjusting?

Topics

Related Companies

UsernamePublicRestriction

Register

SC090799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel